For US Residents Only

Prescribing Information

 

Home > COVID 19

Dear Cystinosis Community,

Leadiant Biosciences, Inc. recognizes the challenges as a result of the pandemic due to COVID-19. Our team is sensitive to concerns regarding the availability of critical medications. We are monitoring the pandemic and our supply of Cystaran for the treatment of patients with cystinosis with corneal crystals. Our supply chain is secure at this time and we do not anticipate any shortage including considerations of transport of the medication from the specialty pharmacy to you. Leadiant will update the status of Cystaran supply on our product website cystaran.com as well as providing this information and link to the Cystinosis Research Foundation (CRF) and Cystinosis Research Network (CRN). Please feel free to visit our site at Leadiant.com and contact us with any questions or concerns.

Thank you,
The Leadiant Team

Additional Contact Information:
If you are a patient who has a question specifically for Leadiant, please call 1-800-447-0169 or email info@leadiant.com

If you have a question for Alliance Rx Walgreens Prime, our specialty pharmacy distribution partner, please call 1-877-534-9627

If you would like to contact a cystinosis advocacy group:
Cystinosis Research Foundation www.cystinosisresearch.org
Cystinosis Research Network www.cystinosis.org

To report an adverse event or side effect, please call 1-866-634-2765 or email drugsafety@leadiant.com

If you are a healthcare professional and have any medical questions, please call 1-866-634-2765 or email leadiant@tmacmail.com

Indication:

CYSTARAN (CYSTEAMINE OPHTHALMIC SOLUTION) 0.44% STERILE is a cystine-depleting agent indicated for the treatment of corneal cystine crystal accumulation in patients with cystinosis.

Important Safety Information:

To minimize contaminating the dropper tip and solution, care should be taken not to touch the eyelids or surrounding areas with the dropper tip of the bottle. Keep bottle tightly closed when not in use.

There have been reports of benign intracranial hypertension (or pseudotumor cerebri) associated with oral cysteamine treatment that has resolved with the addition of diuretic therapy. There have also been reports associated with ophthalmic use of cysteamine; however, all of these patients were on concurrent oral cysteamine.

CYSTARAN contains benzalkonium chloride, which may be absorbed by soft contact lenses. Contact lenses should be removed prior to application of solution and may be reinserted 15 minutes following its administration.

CYSTARAN is for topical ophthalmic use only.

The most frequently reported ocular adverse reactions occurring in ≥ 10% of patients were sensitivity to light, redness, and eye pain/irritation, headache and visual field defects.